Immunotherapy in the treatment of advanced or recurrent endometrial cancer

Clin Adv Hematol Oncol. 2024 Apr;22(3):129-139.ABSTRACTThe standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.PMID:38588272
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Authors: Source Type: research